@article {2140, title = {The Analysis of Matrix Metalloproteinase-9 and Tissue Inhibitor Matrix Metalloproteinase-1 Levels in the Amniochorion Membrane Patients on Premature Rupture of Membranes}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {October 2023}, pages = {910-912}, type = {Research Article}, chapter = {910}, abstract = {

Introduction: MMP-9 is essential for extracellular matrix remodeling, which affects the incidence of premature rupture of membranes. In addition, decreased and increased levels of TIMP-1, a preferential MMP-9 inhibitor, have been reported to be associated with premature rupture of membranes because it showed an imbalance in the MMP-9 or TIMP-1 levels. This study aims to analyze MMP-9 and TIMP-1 levels in amniochorion membrane patients on premature rupture of membranes. Methods: An analytic observational study was conducted on 70 subjects. The MMP-9 and TIMP-1 levels in the amniochorion membrane were determined by ELISA. Results: The results of this study indicate that the amniochorion membrane in the incidence of premature rupture of membranes is characterized by increased levels of MMP-9, while TIMP-1 levels do not differ between the incidence of premature rupture of membranes. Conclusion: Based on the research that has been done, it can be concluded that there are differences in protein levels of MMP-9 but there are no differences in protein levels of TIMP-1 in premature rupture of membranes

}, keywords = {MMP-9, Premature rupture of membranes., TIMP-1}, doi = {10.5530/pj.2023.15.173}, author = {Meidrin Joni and Eryati Darwin and Herlambang Herlambang and Aisyah Elliyanti} } @article {2030, title = {Mechanism of High Dosage Vitamin D Supplementation on The Lung Function and Quality of Life of Stable COPD Patients}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {June 2023}, pages = {274-278}, type = {Original Article }, chapter = {274}, abstract = {

Background: Oxidative stress results from the amplification mechanism of COPD, which leads to decreased lung function and the quality of life of the sufferers. Vitamin D has a function in reducing oxidative stress levels through several mechanisms, which can be revealed by analyzing several biomarkers to determine the role of vitamin D on lung function and the quality of life of stable COPD patients. Methods: The subjects included GOLD 2 and 3 stable COPD patients who had 25(OH)D levels of \< 32 ng/ml and were receiving bronchodilator Indacaterol maleate therapy. The biomarkers examined included Nrf2, HDAC2, MDA, MMP-9, pulmonary function tests 6MWT, and QOL. The patients in the control and treatment groups were administered with vitamin D at a dose of 1,000 and 5,000 IU, respectively, for three months. Results: The administration of vitamin D to the patients in the control and treatment groups can significantly reduce oxidative stress, as evidenced by reduced MDA (p-value \< 0.01) and MMP-9 levels (p-value \< 0.01). Vitamin D affects exercise tolerance, as evidenced by 6MWT (p-value = 0.01). Vitamin D affects the quality of life, as evidenced by 6MWT (p-value = 0.01). Vitamin D affects Nrf2 levels (p-value = 0.08) and HDAC2 (p-value = 0.01). Conclusion: The pathway analysis through the study of the Nrf2, HDAC2, MMP-9, and MDA levels does not prove that vitamin D can prevent decreased lung function and quality of life in patients with stable COPD.

}, keywords = {6MWT, COPD, FEF25-75, FEV1, FVC, HDAC2, MDA, MMP-9, Nrf2, Oxidative stress, QOL., Vitamin D}, doi = {10.5530/pj.2023.15.74}, author = {Adyan Donastin and Muhammad Amin and Yulistiani} } @article {1817, title = {Effects of Hyperbaric Oxygen Therapy on the Expression of FGF, MMP-9 and Occludin in the Repair of Gastric Mucosal Erosions}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {June 2022}, pages = {660-671}, type = {Research Article}, chapter = {660}, abstract = {

This study was conducted to evaluate the immunohistochemical (IHC) expression of fibroblast growth factor (FGF), matrix metalloproteinase-9 (MMP-9) and occludin in the repair of gastric mucosal erosions in Wistar rats was induced by administration of aspirin, one of the non-steroidal anti-inflammatory drugs (NSAIDs). These expressions are associated with changes in histopathological features. This experimental research used a posttest only control group design. The research sample was 28 male Wistar rats that met the inclusion criteria, but not met the exclusion criteria. The samples were randomly allocated into four groups. Group 1 as negative control and group 2 as positive control. Group 3 as treatment 1, which was given HBOT (hyperbaric oxygen therapy) 2.4 ATA for 3 x 30 minutes/day (air break 5 minutes) for 5 days, after aspirin induction at 30 mg/kgBW/day for 10 days. Group 4 as treatment 2, which was given HBOT 2.4 ATA for 3 x 30 minutes/day (air break 5 minutes) for 10 days, after aspirin induction at 30 mg/kgBW/day for 10 days. Each group was evaluated the immunohistochemical (IHC) expression of FGF, MMP-9 and occludin, using the Remmele scale index, immune reactive score (IRS). The expressions were correlated with histopathological changes, using the HAI (Histology Activity Index) method. The results show that the HBOT 2.4 ATA for 3 x 30 minutes/day (air break 5 minutes) for 5 days and for 10 days, it can improve FGF (p=0.016) and occludin (p=0.021) expression significantly. The HBOT can also reduce inflammation (p=0.005), epithelial defects (p\<0.001) and MMP-9 expression (0.042). There is a significant difference in occludin expression (p=0.034) between 5-day HBOT and 10-day HBOT. However, there was no significant difference between the 5-day HBOT and the 10-day HBOT for reduce inflammation (p=0.845), epithelial defects (p=0.469), FGF expression (0.054) and MMP-9 expression (0.470). The provision of HBOT at 2.4 ATA significantly improved gastric mucosal erosion in NSAID-induced gastric mucosal erosion Wistar rats model, by decreasing MMP-9 expression, as well as increasing FGF and occludin expression. There is a significant difference in occludin expression between 5-day HBOT and 10-day HBOT.

}, keywords = {FGF, Gastric mucosal erosions, HBOT, MMP-9, Occludin.}, doi = {10.5530/pj.2022.14.85}, author = {M. Fathi Ilmawan and Soetjipto and M. Guritno Suryokusumo and M. Miftahussurur} }